The FY2025 (Dec) proxy of Atea Pharmaceuticals names 19 peer companies for pay. Among Atea Pharmaceuticals and these peers, CEO pay was 4th highest of 6 and total shareholder return was the lowest of 6.
4th highest of 6in Atea Pharmaceuticals and its pay peers, FY2025 (Dec) by CEO pay:
$1.4M$33.3M
6th highest of 6in Atea Pharmaceuticals and its pay peers, FY2025 (Dec) by total shareholder return:
$9$487
Pay peer group, FY2025 (Dec) proxy
| Scholar Rock Holding | ||
| Vir Biotechnology | ||
| Replimune Group | ||
| Gossamer Bio | ||
| Arbutus Biopharma | ||
| 89bio, Inc. | Not disclosed | Not disclosed |
| Alector, Inc. | Not disclosed | Not disclosed |
| Allakos Inc. | Not disclosed | Not disclosed |
| AlloVir, Inc. | Not disclosed | Not disclosed |
| Anaptys Bio, Inc. | Not disclosed | Not disclosed |
| Annexion, Inc. | Not disclosed | Not disclosed |
| Arcturus Therapeutics Holdings | Not disclosed | Not disclosed |
| Assembly Biosciences, Inc. | Not disclosed | Not disclosed |
| Chimerix, Inc. | Not disclosed | Not disclosed |
| Enanta Pharmaceuticals, Inc. | Not disclosed | Not disclosed |
| Inozyme Pharma, Inc. | Not disclosed | Not disclosed |
| Invivyd, Inc. | Not disclosed | Not disclosed |
| Kodiak Sciences Inc. | Not disclosed | Not disclosed |
| Y-mABs Therapeutics, Inc. | Not disclosed | Not disclosed |
19 companies
Changes by year
FY2025 (Dec) proxy
- Added89bio, Inc.pay peer groupTo ensure an appropriate number of peers for reference, five companies meeting our criteria for the 2025 Peer Group, being 89bio, Inc., Annexion, Inc., Assembly Biosciences, Inc., Gossamer Bio, Inc. and Inozyme Pharma, Inc. were added
- AddedAnnexion, Inc.pay peer groupTo ensure an appropriate number of peers for reference, five companies meeting our criteria for the 2025 Peer Group, being 89bio, Inc., Annexion, Inc., Assembly Biosciences, Inc., Gossamer Bio, Inc. and Inozyme Pharma, Inc. were added
- AddedAssembly Biosciences, Inc.pay peer groupTo ensure an appropriate number of peers for reference, five companies meeting our criteria for the 2025 Peer Group, being 89bio, Inc., Annexion, Inc., Assembly Biosciences, Inc., Gossamer Bio, Inc. and Inozyme Pharma, Inc. were added
- AddedGossamer Biopay peer groupTo ensure an appropriate number of peers for reference, five companies meeting our criteria for the 2025 Peer Group, being 89bio, Inc., Annexion, Inc., Assembly Biosciences, Inc., Gossamer Bio, Inc. and Inozyme Pharma, Inc. were added
- AddedInozyme Pharma, Inc.pay peer groupTo ensure an appropriate number of peers for reference, five companies meeting our criteria for the 2025 Peer Group, being 89bio, Inc., Annexion, Inc., Assembly Biosciences, Inc., Gossamer Bio, Inc. and Inozyme Pharma, Inc. were added
- RemovedKura Oncologypay peer groupdue to their respective market capitalization being outside our defined range, as well as Point Biopharma Global Inc. (acquired by Eli Lilly) and VBI Vaccines Inc. (filed for bankruptcy)
- RemovedPoint Biopharma Global Inc.pay peer groupdue to their respective market capitalization being outside our defined range, as well as Point Biopharma Global Inc. (acquired by Eli Lilly) and VBI Vaccines Inc. (filed for bankruptcy)
- RemovedRocket Pharmaceuticalspay peer groupdue to their respective market capitalization being outside our defined range, as well as Point Biopharma Global Inc. (acquired by Eli Lilly) and VBI Vaccines Inc. (filed for bankruptcy)
- RemovedSummit Therapeuticspay peer groupdue to their respective market capitalization being outside our defined range, as well as Point Biopharma Global Inc. (acquired by Eli Lilly) and VBI Vaccines Inc. (filed for bankruptcy)
- RemovedVBI Vaccines Inc.pay peer groupdue to their respective market capitalization being outside our defined range, as well as Point Biopharma Global Inc. (acquired by Eli Lilly) and VBI Vaccines Inc. (filed for bankruptcy)
'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3cclipPath%20id='clip-path-2'%3e%3cpath%20id='Path_4394'%20d='M4.892,12.4c.758.192,1.629.412,2.67.6a27,27,0,0,0,5.02.426,18.387,18.387,0,0,0,4.07-.6,15.613,15.613,0,0,1,3.2-.6,2.179,2.179,0,0,1,1.861.814,3.668,3.668,0,0,1,.542,1.724c.058.524.058.872.35,1.086a3.609,3.609,0,0,0,1.821.31c.95.02,2.268-.02,3.12-.058s1.24-.077,1.531.1a1.153,1.153,0,0,1,.485.989,10.163,10.163,0,0,0-.136,1.3,2.4,2.4,0,0,0,.717,1.142,4.087,4.087,0,0,1,.872,1.222.844.844,0,0,1-.446,1.066,5.765,5.765,0,0,1-2.171.5,10.913,10.913,0,0,0-2.326.271c-.465.194-.426.581-.155.988s.776.833,1.028,1.3a1.084,1.084,0,0,1-.136,1.357,4.056,4.056,0,0,1-1.977.814c-.814.155-1.667.194-2.442.329a12.864,12.864,0,0,0-1.978.543c-.5.175-.814.291-.969.621a.85.85,0,0,0,.427,1.163,13.866,13.866,0,0,0,2.616.5c.872.175,1.453.484,1.55,1.047a13.544,13.544,0,0,1-.368,2.229,3.628,3.628,0,0,0,.523,2.267,1.967,1.967,0,0,0,1.589.755,8,8,0,0,0,2.364-.077,8.558,8.558,0,0,0,1.822-.736,1.836,1.836,0,0,1,1.861-.1,4.294,4.294,0,0,1,1.182,2.326c.194.872.155,1.569.891,2.015a14.815,14.815,0,0,0,3.664.93A14,14,0,0,1,41.4,42.242a9.687,9.687,0,0,1,1.736,1.229A24.91,24.91,0,1,0,4.892,12.4'%20transform='translate(-4.892%20-0.176)'%20fill='%23224a7c'/%3e%3c/clipPath%3e%3c/defs%3e%3cg%20id='Group_3541'%20transform='translate(-0.094%20-0.128)'%3e%3cg%20id='Group_3282'%20transform='translate(0.094%2015.73)'%3e%3cg%20id='Group_3281'%20clip-path='url(%23clip-path)'%3e%3crect%20id='Rectangle_2848'%20width='33.837'%20height='20.982'%20transform='translate(-0.094%2033.75)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3cg%20id='Group_3284'%20transform='translate(3.563%200.128)'%3e%3cg%20id='Group_3283'%20clip-path='url(%23clip-path-2)'%3e%3crect%20id='Rectangle_2849'%20width='43.423'%20height='46.468'%20transform='translate(-0.12%2043.294)%20rotate(-89.841)'%20fill='%23224a7c'/%3e%3c/g%3e%3c/g%3e%3c/g%3e%3c/svg%3e)
FY2024 (Dec) proxy
- AddedAnaptys Bio, Inc.pay peer groupTo ensure an appropriate number of peers for reference, four companies meeting our criteria for the 2024 Peer Group, being Anaptys Bio, Inc., Arbutus Biopharma Corporation, Chimerix, Inc. and Scholar Rock Holding Corporation, were added
- AddedArbutus Biopharmapay peer groupTo ensure an appropriate number of peers for reference, four companies meeting our criteria for the 2024 Peer Group, being Anaptys Bio, Inc., Arbutus Biopharma Corporation, Chimerix, Inc. and Scholar Rock Holding Corporation, were added
- AddedChimerix, Inc.pay peer groupTo ensure an appropriate number of peers for reference, four companies meeting our criteria for the 2024 Peer Group, being Anaptys Bio, Inc., Arbutus Biopharma Corporation, Chimerix, Inc. and Scholar Rock Holding Corporation, were added
- AddedScholar Rock Holdingpay peer groupTo ensure an appropriate number of peers for reference, four companies meeting our criteria for the 2024 Peer Group, being Anaptys Bio, Inc., Arbutus Biopharma Corporation, Chimerix, Inc. and Scholar Rock Holding Corporation, were added
- RemovedAkero Therapeutics, Inc.pay peer groupdue to their respective market capitalization being outside our defined range
- RemovedArcus Biosciences, Inc. ChemoCentryx, Inc. (acquired by Amgen)pay peer groupdue to their respective market capitalization being outside our defined range
- RemovedMadrigal Pharmaceuticalspay peer groupdue to their respective market capitalization being outside our defined range
- RemovedSpringworks Therapeutics, Inc.pay peer groupdue to their respective market capitalization being outside our defined range
FY2023 (Dec) proxy
- AddedMadrigal Pharmaceuticalspay peer groupTo ensure an appropriate number of peers for reference, two companies meeting our criteria for the 2023 Peer Group, being Madrigal Pharmaceuticals, Inc. and Point Biopharma Global Inc., were added
- AddedPoint Biopharma Global Inc.pay peer groupTo ensure an appropriate number of peers for reference, two companies meeting our criteria for the 2023 Peer Group, being Madrigal Pharmaceuticals, Inc. and Point Biopharma Global Inc., were added
- RemovedArvinaspay peer groupas a result of its acquisition during 2022 and the other two companies were removed due to their respective market capitalization being outside our defined range
- RemovedQuince Therapeutics (formerly known as Cortezyme, Inc.)pay peer groupas a result of its acquisition during 2022 and the other two companies were removed due to their respective market capitalization being outside our defined range
- RemovedTurning Point Therapeutics, Inc. Turning Point Therapeutics, Inc.pay peer groupas a result of its acquisition during 2022 and the other two companies were removed due to their respective market capitalization being outside our defined range
The comes from the company's proxy. CEO pay and of each company come from its own Pay versus Performance table for the same fiscal year. Each company counts TSR from its own start year, so two values compare only when the start years match.